Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by Biotech777on Apr 24, 2014 12:27pm
175 Views
Post# 22486717

RE:RE:INTERESTING REPORT FROM ACC PRESENTATION ON evolocumab :

RE:RE:INTERESTING REPORT FROM ACC PRESENTATION ON evolocumab :
JK,

1. Yes. LDL can be brought down too low. LDL is a primary lipid/ cholesterol transporter to cells. Unmodified LDL is not bad. What is bad is modified (acetylated or oxidized LDL). This modification occurs primarily within the arterial wall and is a major culprit for destabilization of vulnerable plaques.  Too little LDL and cells don't get enough cholesterol which they need for many functions including division. How low is too low depends largely on the method of inhibiting LDL. This therapy will largely be targeted at those who are intolerant or refractory to statins so their LDL will already be very high.

2. Yes, this is what the statin data is based on. Additionally the theory goes that one way to reduce oxLDL within the arterial wall is to reduce plasma levels of normal LDL.

3. Most are by injection including amgens but there are some that can be given orally but they are much further behnd in development. The injectables look to be a once or twice a month dosing.
Bullboard Posts